Evidence map›Paper›PMID 26600780›Full record

ArticleCase reports in oncology

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Corey A Carter, Aiste Degesys, Bryan Oronsky, Jan Scicinski, Scott Z Caroen, Arnold L Oronsky, Tony Reid, Pedro Cabrales, Joe Roswarski

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. RRx-001 protects against cisplatin-induced toxicities.Journal of cancer research and clinical oncology · 2017
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Corey A CarterWalter Reed National Military Medical Center, Bethesda, Md., USA.
Aiste DegesysWalter Reed National Military Medical Center, Bethesda, Md., USA.
Bryan OronskyEpicentRx, Inc., Mountain View, Calif., USA.
Jan ScicinskiEpicentRx, Inc., Mountain View, Calif., USA.
Scott Z CaroenEpicentRx, Inc., Mountain View, Calif., USA.
Arnold L OronskyInterWest Partners, Menlo Park, Calif., USA.
Tony ReidMoores Cancer Center, University of California, La Jolla, Calif., USA.
Pedro CabralesDepartment of Bioengineering, University of California, La Jolla, Calif., USA.
Joe RoswarskiWalter Reed National Military Medical Center, Bethesda, Md., USA.
Epicentre (South Africa) · ZAWalter Reed National Military Medical Center · USLa Jolla Bioengineering Institute · USMoores Cancer Center

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms defined by the presence of cells with secretory granules and the potential to produce and release high levels of vasoactive peptides into the circulation, leading to severe flushing and diarrhea, which may adversely affect quality of life. This report presents the case of a 64-year-old man with chronic refractory diarrhea due to pulmonary NET treated with the experimental anticancer agent RRx-001 in a phase II trial called TRIPLE THREAT with subsequent resolution of his diarrhea.

Indexed as

Carcinoid syndromeEpigeneticsNeuroendocrine tumor

Identifiers

PMID26600780
PMCPMC4649750
OpenAlexW2177301634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.